

Stefan Prekovic

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5770706/publications.pdf>

Version: 2024-02-01

24
papers

1,262
citations

471477

17
h-index

610883

24
g-index

30
all docs

30
docs citations

30
times ranked

2393
citing authors

#	ARTICLE	IF	CITATIONS
1	Loss of p53 triggers WNT-dependent systemic inflammation to drive breast cancer metastasis. <i>Nature</i> , 2019, 572, 538-542.	27.8	312
2	Structure of the homodimeric androgen receptor ligand-binding domain. <i>Nature Communications</i> , 2017, 8, 14388.	12.8	131
3	Androgen receptor antagonists for prostate cancer therapy. <i>Endocrine-Related Cancer</i> , 2014, 21, T105-T118.	3.1	116
4	Emerging mechanisms of enzalutamide resistance in prostate cancer. <i>Nature Reviews Urology</i> , 2014, 11, 712-716.	3.8	107
5	The Effect of F877L and T878A Mutations on Androgen Receptor Response to Enzalutamide. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1702-1712.	4.1	73
6	Single-cell ATAC and RNA sequencing reveal pre-existing and persistent cells associated with prostate cancer relapse. <i>Nature Communications</i> , 2021, 12, 5307.	12.8	58
7	Enzalutamide therapy for advanced prostate cancer: efficacy, resistance and beyond. <i>Endocrine-Related Cancer</i> , 2019, 26, R31-R52.	3.1	49
8	Drivers of AR indifferent anti-androgen resistance in prostate cancer cells. <i>Scientific Reports</i> , 2019, 9, 13786.	3.3	44
9	The Role of Single Nucleotide Polymorphisms in Predicting Prostate Cancer Risk and Therapeutic Decision Making. <i>BioMed Research International</i> , 2014, 2014, 1-16.	1.9	35
10	Glucocorticoid receptor triggers a reversible drug-tolerant dormancy state with acquired therapeutic vulnerabilities in lung cancer. <i>Nature Communications</i> , 2021, 12, 4360.	12.8	35
11	Comparative Genomic and Transcriptomic Analyses of LNCaP and C4-2B Prostate Cancer Cell Lines. <i>PLoS ONE</i> , 2014, 9, e90002.	2.5	35
12	Genomic and epigenomic analysis of high-risk prostate cancer reveals changes in hydroxymethylation and TET1. <i>Oncotarget</i> , 2016, 7, 24326-24338.	1.8	33
13	Duality of glucocorticoid action in cancer: tumor-suppressor or oncogene?. <i>Endocrine-Related Cancer</i> , 2021, 28, R157-R171.	3.1	31
14	Molecular underpinnings of enzalutamide resistance. <i>Endocrine-Related Cancer</i> , 2018, 25, R545-R557.	3.1	28
15	TLE3 loss confers AR inhibitor resistance by facilitating GR-mediated human prostate cancer cell growth. <i>ELife</i> , 2019, 8, .	6.0	25
16	Endonuclease FEN1 Coregulates ER \pm Activity and Provides a Novel Drug Interface in Tamoxifen-Resistant Breast Cancer. <i>Cancer Research</i> , 2020, 80, 1914-1926.	0.9	23
17	Identification of mineralocorticoid receptor target genes in the mouse hippocampus. <i>Journal of Neuroendocrinology</i> , 2019, 31, e12735.	2.6	22
18	A CRISPR-Cas9 screen identifies essential CTCF anchor sites for estrogen receptor-driven breast cancer cell proliferation. <i>Nucleic Acids Research</i> , 2019, 47, 9557-9572.	14.5	21

#	ARTICLE	IF	CITATIONS
19	The androgen receptor depends on ligandâ€™binding domain dimerization for transcriptional activation. EMBO Reports, 2021, 22, e52764.	4.5	20
20	Androgen and glucocorticoid receptor direct distinct transcriptional programs by receptor-specific and shared DNA binding sites. Nucleic Acids Research, 2021, 49, 3856-3875.	14.5	17
21	The role of TET-mediated DNA hydroxymethylation in prostate cancer. Molecular and Cellular Endocrinology, 2018, 462, 41-55.	3.2	15
22	Treatment-induced changes in the androgen receptor axis: Liquid biopsies as diagnostic/prognostic tools for prostate cancer. Molecular and Cellular Endocrinology, 2018, 462, 56-63.	3.2	12
23	Multidisciplinary investigation links backward-speech trait and working memory through genetic mutation. Scientific Reports, 2016, 6, 20369.	3.3	5
24	Ribociclib Induces Broad Chemotherapy Resistance and EGFR Dependency in ESR1 Wildtype and Mutant Breast Cancer. Cancers, 2021, 13, 6314.	3.7	3